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Abstract: In 2019, it was estimated that 2.5 million people die from lower tract respiratory infections
annually. One of the main causes of these infections is Staphylococcus aureus, a bacterium that
can invade and survive within mammalian cells. S. aureus intracellular infections are difficult
to treat because several classes of antibiotics are unable to permeate through the cell wall and
reach the pathogen. This condition increases the need for new therapeutic avenues, able to deliver
antibiotics efficiently. In this work, we obtained outer membrane vesicles (OMVs) derived from
the myxobacteria Cystobacter velatus strain Cbv34 and Cystobacter ferrugineus strain Cbfe23, that are
naturally antimicrobial, to target intracellular infections, and investigated how they can affect the
viability of epithelial and macrophage cell lines. We evaluated by cytometric bead array whether
they induce the expression of proinflammatory cytokines in blood immune cells. Using confocal
laser scanning microscopy and flow cytometry, we also investigated their interaction and uptake into
mammalian cells. Finally, we studied the effect of OMVs on planktonic and intracellular S. aureus.
We found that while Cbv34 OMVs were not cytotoxic to cells at any concentration tested, Cbfe23
OMVs affected the viability of macrophages, leading to a 50% decrease at a concentration of 125,000
OMVs/cell. We observed only little to moderate stimulation of release of TNF-alpha, IL-8, IL-6 and
IL-1beta by both OMVs. Cbfe23 OMVs have better interaction with the cells than Cbv34 OMVs, being
taken up faster by them, but both seem to remain mostly on the cell surface after 24 h of incubation.
This, however, did not impair their bacteriostatic activity against intracellular S. aureus. In this study,
we provide an important basis for implementing OMVs in the treatment of intracellular infections.
Keywords: extracellular vesicles; antimicrobial resistance; Staphylococcus aureus; intracellular infection;
outer membrane vesicles; biogenic drug carriers
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1. Introduction
Pulmonary infections represent a serious health risk for today’s society. The Global Burden of
Disease Study 2016 has estimated that lower respiratory infections are one of the leading causes of death
worldwide, especially in children aged five years and younger [1,2]. Lung infection is also a frequent
complication for patients with cystic fibrosis (CF), an inherited, systemic disorder caused by a mutation
in the cystic fibrosis trans-membrane regulator channel [3,4]. CF lung disease is characterized by the
accumulation of a thick mucus in the airway, which favors lung inflammation and persistent, chronic
bacterial infection. One of the main pathogens causing lung infections in CF patients is Staphylococcus
aureus (S. aureus) [5,6]. Besides being able to form biofilms, it is known that S. aureus can also invade
professional and non-professional phagocytes and is able to survive intracellularly by escaping the
endosomal pathway into the cytoplasm [7–10].
The antibiotics currently available on the market are not optimal for treating intracellular infections,
as most of them need higher concentrations and a longer therapy time to induce a positive effect [11].
Generally, free antibiotics (e.g., aminoglycosides) are unable to eradicate intracellular infections due to
their hydrophilic characteristics and high polarity, which prevent their permeation into mammalian
cells [12–17]. To address this problem, increased efforts have been made towards improved drug
delivery using nanotechnology, surface modification, biomimetic and biogenic carriers to overcome
this barrier [18–21]. Carriers such as liposomes have been successful at delivering antibiotics to biofilms
and eradicating them [22].
Myxobacteria are a group of Gram-negative bacteria that are abundant in soil. Many of
these bacteria show predatory behavior [23], and interact, move and prey by forming coordinated
swarms [24]. They belong to the class Delta Proteobacteria, phylum Proteobacteria. Myxobacteria
are potent producers of antimicrobial compounds [25–28] and they are non-pathogenic to humans.
Outer membrane vesicles (OMVs) are nanoparticles shed from the outer membrane of Gram-negative
bacteria [29–31]. OMVs derived from myxobacteria have been shown to be involved in intercolony
communication but also as predatory weapons against other bacteria [32]. We recently reported on
myxobacterial OMVs with inherent antimicrobial properties due to their cystobactamid cargo [33].
Cystobactmids are topoisomerase inhibitors that have potent antibacterial activity [34]. However,
the antimicrobial activity of myxobacterial OMVs has only been shown against the planktonic model
bacterium (Escherichia coli strain DH5-alpha), which is not clinically relevant. Here, we expand the
evaluation of these OMVs to clinically important S. aureus pathogens. For potential OMV translation,
it is necessary to biotechnologically obtain them at large amounts. Myxobacterial cultures are suitable
for this purpose, because they can be increased to several liters, which facilitates the large-scale isolation
of their OMVs [34].
In this study, we explore the myxobacterial strains Cystobacter velatus Cbv34 and Cystobacter
ferrugineus Cbfe23 for the production of natural antibacterial OMVs and analyze their potential for
uptake by mammalian cells and the eradication of intracellular S. aureus. Our results show that both
Cbv34 and Cbfe23 OMVs are efficiently taken up into macrophages and epithelial cells without affecting
their viability. Importantly, they presented an antibacterial effect against intracellular S. aureus.
2. Materials and Methods
2.1. Myxobacterial Culture
The myxobacterial strains Cbv34 (Cystobacter velatus) and Cbfe23 (Cystobacter ferrugineus) were
cultured in 100 mL M-Medium (w/v, 1.0% phytone, 1.0% maltose, 0.1% CaCl2, 0.1% MgSO4, 50 mM
HEPES, pH adjusted to 7.2 with KOH) at 30 ◦C and 180 rpm. Upon reaching the stationary phase at
6–7 days, 50 mL of the culture was removed for OMV isolation. The remaining volume was used as
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an inoculum for the next passage of the myxobacterial culture. Growth curves of the cultures were
established as described in a previous study [33].
2.2. Isolation and Purification of Outer Membrane Vesicles
In order to obtain potent OMVs with a high yield, the myxobacteria were cultured for at least three
passages prior to performing the isolation. Fifty milliliters of the cultures were used and centrifuged at
9500 × g for 10 min at 4 ◦C. The supernatant was transferred to a new falcon tube and centrifuged
once again at 9500 × g, for 15 min at 4 ◦C. Thirty milliliters of the resulting supernatant was added
into an ultracentrifugation tube and pelleted at 100,000 × g for 2 h at 4 ◦C using a rotor type SW 32 Ti
(Beckman Coulter). The supernatant was removed, and the pellet was dispersed in 300 µL phosphate
buffered saline (PBS, Gibco PBS tablets without calcium, magnesium and phenol red) (Sigma-Aldrich;
Co., St. Louis, MO, USA) filtered with 0.2 µm mixed cellulose ester filters (Whatman, GE Healthcare
UK Limited, Little Chalfont, UK). In order to remove the free protein present in the pellet, a size
exclusion chromatography (SEC) was performed. The pellet was added to a 60 mL column filled with
35–40 mL of Sepharose CL-2B (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) in PBS. One milliliter
fractions of OMVs in PBS were collected into polypropylene (PP) tubes (Axygen, Corning Incorporated,
Reynosa, Mexico) next to a Bunsen burner, to obtain aseptic conditions. The fractions were kept at
4 ◦C for up to one month. Prior to infection, experiments and measurements of particle parameters,
the fractions were filtered with Puredisc 25 AS (GE Healthcare UK Limited, Little Chalfont, UK) to
assure sterility.
2.3. Liquid-Chromatography Coupled Mass Spectrometry
2.3.1. OMV Preparation
OMV pellets were resuspended in 500 µL of particle-free PBS and lyophilized for 16 h. The dried
pellet was mixed with 300 µL of MeOH and vortexed for 1–2 min. The OMV extract was centrifuged
to remove debris. Then, the supernatant was transferred to a vial for LC-MS analysis.
2.3.2. UHPLC MS Conditions
UPLC-hrMS analysis was performed on a Dionex (Germering, Germany) Ultimate 3000 RSLC
system using a Waters (Eschborn, Germany) BEH C18 column (50 × 2.1 mm, 1.7 µm) equipped with a
Waters VanGuard BEH C18 1.7 µm guard column. Separation of 1 µl sample was achieved by a linear
gradient from (A) H2O + 0.1% FA to (B) ACN + 0.1% FA at a flow rate of 600 µL/min and a column
temperature of 45 ◦C. Gradient conditions were as follows: 0–0.5 min, 5% B; 0.5–18.5 min, 5%–95% B;
18.5–20.5 min, 95% B; 20.5–21 min, 95%–5% B; 21–22.5 min, 5% B. UV spectra were recorded by a DAD
in the range 200–600 nm. The LC flow was split to 75 µL/min before entering the Bruker Daltonics
maXis 4G hrToF mass spectrometer (Bremen, Germany) using the Apollo II ESI source. Mass spectra
were acquired in centroid mode ranging from 150–2500 m/z (mass/charge) at a 2 Hz full scan rate.
Mass spectrometry source parameters are set to 500 V as end plate offset; 4000 V as capillary voltage;
nebulizer gas pressure 1 bar; dry gas flow of 5 L/min and a dry temperature of 200 ◦C. Ion transfer
and quadrupole settings are set to Funnel RF 350 Vpp; Multipole RF 400 Vpp as transfer settings and
Ion energy of 5 eV as well as a low mass cut of 300 m/z as Quadrupole settings. Collision cell is set to
5.0 eV and pre pulse storage time is set to 5 µs. Spectra acquisition rate is set to 2 Hz. Calibration is
done automatically before every LC-MS run by the injection of sodium formate and calibration on the
sodium formate clusters forming in the ESI source. All MS analyses are acquired in the presence of the
lock masses C12H19F12N3O6P3; C18H19O6N3P3F2 and C24H19F36N3O6P3, which generate the [M + H]+
ions of 622.03; 922.01 and 1221.10.
Cells 2020, 9, 194 4 of 17
2.3.3. LC-MS Data Bucketing and Annotation Using Metaboscape Software
Acquired LC-MS data are bucketed by Bruker Metaboscape 4.0 SR1 using the qTOF data optimized
TReX 3D algorithm. Bucketed analyses are checked for library hits against our in-house database of
myxobacterial natural products called myxobase. Library hits are retained if they show a retention
time deviation under the described parameters of less than 0.2 min, m/z value deviation of less than
5 ppm and isotope pattern ratio congruence lower than 30 milliSigma.
2.3.4. Conditions for MS2 Analysis
LC and MS conditions for automatic precursor selection MS2 data acquisitions remain as described
in section-standardized UHPLC-MS conditions. CID Energy is ramped from 35 eV for 500 m/z to 45 eV
for 1000 m/z and 60 eV for 2000 m/z. MS full scan acquisition rate was set to 2 Hz and MS/MS spectra
acquisition rates were ramped from 1 to 4 Hz for precursor ion intensities of 10 to 1000 kcts.
2.3.5. GNPS Clustering Parameters
MS2 data of the vesicle extracts were uploaded to the Global Natural Product Social Molecular
Networking (GNPS) server at University of California San Diego [35]. A molecular network was
created, using a parent mass tolerance of 0.05 Da and a fragment ion tolerance of 0.1 Da. Cosine score
of edges considered to network was set to extend 0.7 and the minimum matched fragment peaks
were set to 5. The clustered dataset was visualized using Cytoscape 3.7.2 (Cytoscape Consortium,
UCSD San Diego, USA).
2.4. Cryogenic Electron Microscopy
Cryogenic transmission electron microscopy (cryo-TEM) was performed on OMVs pellets after
ultracentrifugation and purified fractions as previously described [33]. Three to four microliters of the
sample were dropped onto a holey carbon grid (type S147-4, Plano, Wetzlar, Germany) and plotted for
2 s before plunging into liquid ethane at T= −165 ◦C using a Gatan (Pleasanton, CA, USA) CP3 cryo
plunger. The sample was transferred under liquid nitrogen to a Gatan model 914 cryo-TEM sample
holder and analyzed at T = −173 ◦C by low-dose TEM bright-field imaging using a JEOL (Tokyo, Japan)
JEM-2100 LaB6 at 200 kV accelerating voltage. Images with 1024 × 1024 pixels were acquired using a
Gatan Orius SC1000 CCD camera at 2 s binning and 4 s imaging time.
2.5. Cell Culture
The murine macrophage cell line RAW 264.7 was obtained from the European Collection of
Authenticated Cell Cultures (ECACC) and cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(1X) (Life Technologies Limited, Paisley, UK) supplemented with 10% (v/v) fetal bovine serum (FBS)
(Life Technologies Limited, Paisley, UK). The adenocarcinomic human alveolar basal epithelial cell
line (A549) and the human acute leukemia monocyte cell line (THP-1) were both purchased from the
German Collection of Microorganisms and Cell Cultures (DSMZ) and cultured in RPMI 1640 (Life
Technologies Limited, Paisley, UK) supplemented with 10% (v/v) FBS. RAW264.7 and A549 cells were
split once a week, starting with 0.2 × 106 cells/13 mL for RAW and A549. THP-1 cells were split twice a
week to a seeding density of 2–3 × 106 cells/13 mL. Mycoplasma tests were conducted regularly.
2.6. Cell Viability and Cytotoxicity
To assess the viability and cytotoxicity of cells upon treatment, the cells were seeded into 96-well
plates at a density of 20,000 cells/well (RAW 264.7 and A549) and 100,000 cells/well (THP-1). To stimulate
the THP-1 cells into macrophages, they were incubated with 30 ng/mL of phorbol 12-myristate 13-acetate
(PMA). All cells were grown for 48 h. Within every set of experiments, a live-control, using cells treated
with PBS (100 µL cell medium plus 100 µL PBS), which did not show any change in cell viability or
morphology, and a dead-control, using cells treated with 1% (v/v) Triton-X 100 (Sigma-Aldrich; Co.,
Cells 2020, 9, 194 5 of 17
St. Louis, MO, USA) were included. During the assays, cells were cultured in FCS-free medium to
prevent falsified results caused by traces of lactate dehydrogenase (LDH) contained in the medium.
Cells were incubated with 100 µL of OMV suspension in PBS at different concentrations (1 × 1012,
1 × 1011 and 1 × 1010 OMVs/mL) and 100 µL of cell medium for 24 h. For cytotoxicity evaluation,
after an incubation time of 24 h, 100 µL of medium were removed to be analyzed by LDH-assay,
which detects the amount of LDH released into the medium upon cell death after plasma membrane
damage, and mixed with 100 µL of LDH-reagent (Roche Diagnostics GmbH, Mannheim, Germany),
prepared according to the supplier’s protocol. After an incubation time of 5 min at room temperature
(RT), the absorbance of the solution was measured at 492 nm. For viability, PrestoBlue (Thermo Fisher
Scientific, Waltham, MA, USA) reagent, which detects metabolically active cells, was diluted by 1 in 10
with the respective medium of the cells. The remaining medium in the wells was removed and 100 µL
of the diluted PrestoBlue reagent was added. After 20 min of incubation at 37 ◦C, fluorescence of the
emerging dye was measured at an excitation of 560 nm and emission of 590 nm with a Tecan Infinity
Pro 200 (Tecan, Männedorf, Switzerland). plate reader.
2.7. Cytokine Detection of OMV-Treated PBMCs
Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation from buffy coats,
derived from three different donors obtained from the Blood Donation Center, Saarbrücken, Germany,
authorized by the local ethics committee (State Medical Board of Registration, Saarland, Germany;
permission no. 173/18). The cells were cultured in a 96-well plate with 100,000 cells per well in RPMI
1640 (Sigma Aldrich, St. Louis, MO, USA). Pellets of OMVs were isolated by ultracentrifugation as
described above. One-hundred microliters of sterile PBS was used to resuspend the pellets. The particle
concentration was determined via nanoparticle tracking analysis and the samples were diluted with
PBMC medium to a final concentration of 5 × 106 and 5 × 105 particles per cell. After 4 h of incubation
at 37 ◦C, cell supernatants were collected and stored at −80 ◦C for further analysis. A BD cytometric
bead array human inflammatory cytokines kit was used according to manufacturer’s specification to
quantify the concentrations of IL-8, IL-10, Il-6, Il-1 beta, TNF alpha and IL-12p70.
2.8. Antimicrobial Effect upon Storage
The stability of the OMVs’ antimicrobial effect was tested by maintaining the purified fractions
at 4 ◦C for up to four weeks before testing them against E. coli DH5-alpha. After treating E. coli with
different dilutions of OMVs for 18 h at 37 ◦C, the optical density was measured at 600 nm with a
plate reader.
2.9. Bacteriomimetic Liposome Preparation
Bacteriomimetic liposomes were prepared by thin film hydration, as previously
reported, with minor modifications [36]. A 6% (w/v) phospholipid solution was prepared
by dissolving 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (POPE),
1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt) (POPG)
and 1,1′,2,2′-tetra-(9Z-octadecenoyl) cardiolipin (sodium salt) (CL) (Avanti Polar Lipids Inc., Alabaster,
AL, USA) (weight ratio 70:20:10) in 5 mL of a chloroform-methanol blend (2:1) in a 250 mL round
bottom flask. A Rotavapor R-205 (BÜCHI Labortechnik GmbH, Essen, Germany) was employed to
remove the solvent under low pressure (60 min, 200 mbar, 135 rpm, 80 ◦C; 30 min, 40 mbar, 135 rpm,
80 ◦C). The remaining lipid film was rehydrated by adding 5 mL PBS (pH 7.4) containing 10% (v/v)
ethanol and rotating for 60 min (70 ◦C, 135 rpm, atmospheric pressure). The obtained liposomes were
sonicated for 60 min followed by 10 extrusion cycles at 70 ◦C, employing a Liposofast L-50 extruder
(Avestin Europe GmbH, Mannheim, Germany).
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2.10. Flow Cytometry and Confocal Laser Scanning Microscopy to Assess OMV Uptake into Mammalian Cells
Purified fractions of OMVs and a suspension of the bacteriomimetic liposome control were
incubated with 2 µL of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI)
(Molecular Probes Inc., Eugene, OR, USA) for 30 min at 37 ◦C. Afterwards, the suspensions were
purified with a 10 mL column filled with Sepharose CL-2B (GE Life Science, UK) in PBS to remove any
unbound dye. The fluorescence of the fractions was measured with a plate reader and the fractions
with the highest concentrations were used. The DiI-stained particles were diluted 1:5 in cell culture
medium with 1% penicillin and streptomycin (v/v) (Life Technologies Corporation, Grand Island, NY,
USA) and incubated with cells at different time points.
For flow cytometry experiments, A549 and RAW 264.7 cells were seeded in 24-well plates with a
density of 2 × 105 cells per well and incubated for 48 h at 37 ◦C and 5% CO2.
Prior to flow cytometry (LSRFortessa, BD Bioscience, San Jose, CA, USA) analysis, the cells were
washed with PBS and detached by using trypsin/EDTA (Life Technologies Limited, Paisley, UK) (A549)
or a cell scraper (RAW 264.7). The cells were diluted with 2% (v/v) FCS in PBS and then added into
FACS tubes for uptake analysis. Cells treated with PBS diluted in mammalian cell culture medium (1:5
dilution) were used as a negative control to set up the Phycoerythrin (PE) channel gate. A 10,000 live
cells threshold was set to be analyzed from forward versus side scatter (FSC vs. SSC) gating. Single
cells were determined by forward height versus forward area scatter (FCS-H vs. FCS-A) gating. The
percentage of positive cells and the mean fluorescence intensity (MFI), which can be used to evaluate
the amount of fluorescent particles taken up by the cells, were determined by analysis with the FlowJo
10.6.1 software (FlowJo LLC, Ashland, OR, USA) using the Phycoerythrin area channel (PE-A).
For confocal laser scanning microscopy (CLSM), the cells were seeded in 8-well chambers (SPL
Life Sciences, Pocheon-si, Gyeonggi-do, Korea) with 4 × 104 cells per well. After the incubation
time points, the cells seeded in the 8-well chambers were washed with PBS and fixed with 3.7% (v/v)
paraformaldehyde in PBS. The cells were stained with Alexa Fluor 488 Phalloidin (Life Technologies
Coorporation, Eugene, OR, USA) for 1 h and DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride)
(Sigma-Aldrich Co., St. Louis, USA) for 30 min, washing the cells with PBS between the staining steps.
The chambers were disassembled and mounted on a coverslip prior to CLSM analysis (Leica TCS SP8,
Leica Microsystems, Wetzlar, Germany). The captured images were processed with the LAS X software
(LAS X 1.8.013370, Leica Microsystems, Wetzlar, Germany).
2.11. Bacterial Culture
Staphylococcus aureus strain Newman and Escherichia coli strain DH5-alpha were obtained from the
DSMZ (German Collection of Microorganisms and Cell Culture). Overnight cultures were prepared
using 20 mL of brain heart infusion (BHI) broth (Becton; Dickinson and Company, Sparks, MD, USA)
for S. aureus and Luria broth (LB) (Sigma-Aldrich; Co., St. Louis, MO, USA) for E. coli inoculated with
a single colony. Cultures were incubated at 37 ◦C and 180 rpm.
2.12. Intracellular Infection
A549 cells were seeded (2 × 104 cells/well) into 96-well plates and incubated for 48 h. Ten milliliters
of the bacterial overnight culture was pelleted at 2000 × g, 4 ◦C, for 5 min and resuspended in PBS. The
bacterial suspension in PBS was then diluted to approximately 2 × 106 colony forming units per mL
(CFU/mL) in mammalian cell medium. The cells were infected for 2 h (approximately multiplicity
of infection (MOI) = 100), following washing with PBS and treatment with 50 µg/mL gentamicin for
30 min. After an additional washing step, cells were treated for 24 h with different concentrations of
OMVs and controls, each diluted in cell culture medium. After 24 h incubation, the cells were lysed
with HBSS (Hanks Buffered Saline Solution) (Life Technologies Limited, Paisley, UK) supplemented
with 0.1% bovine serum albumin (Sigma-Aldrich Co., St. Louis, MO, USA) (w/v) and 0.1% Triton-X
100 (Sigma-Aldrich; Co., St. Louis, MO, USA) (v/v). Serial dilutions were prepared in a PBS solution
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containing 0.05% Tween-20 (Sigma-Aldrich, Co., St. Louis, MO, USA) (v/v) and inoculated on BHI
agar plates (Becton; Dickinson and Company, Sparks, MD, USA), which were then incubated at 37 ◦C
overnight. Afterwards, the single colonies were counted and the CFU/mL values calculated.
2.13. Statistical Analysis
The data is displayed as mean ± standard error of the mean (SEM). The number of independent
experiments (n) is shown in each figure. The experiments and measurements were conducted at least
in triplicates. The results were analyzed by GraphPad Prism 8.3 (GraphPad Software, San Diego, CA,
USA), using Kruskal-Wallis test by ranks, followed by Dunn’s multiple comparisons test. Significant
P-values were illustrated as * p < 0.05, ** p < 0.005, *** p < 0.0005 and **** p < 0.0001.
3. Results
3.1. OMVs are Successfully Isolated by Ultracentrifugation and SEC
The OMVs were isolated from the myxobacterial cultures (Figure S1) and successfully separated
from free proteins remaining in the pellet by SEC (Figure S2), using our standardized protocol [33].
The Cbfe23 OMVs were round-shaped and electron-dense, with a well delimited membrane, shown in
the cryo-TEM micrographs (Figure 1). The main fractions of OMVs were about 120–150 nm in size
(Figure S3). Cbfe23 OMVs had a zeta potential of −5.3 ± 0.7 mV while Cbv34 OMVs showed a zeta
potential of −4.7 ± 0.6 mV, as recently reported by our group [33]. The liposomes used as a control for
the uptake studies had a zeta potential of −24.5 ± 1.2 mV.
Cells 2019, 8, x FOR PEER REVIEW 7 of 19 
Cells 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/cells 
incubated at 37 °C overnight. Afterwards, the single colonies were counted and the CFU/mL values 
calculated. 
2.13. Statistical Analysis 
The data is displayed as mean ± standard error of the mean (SEM). The number of independent 
experiments (n) is shown in each figure. The experiments and measurements were conducted at least 
in triplicates. The results were analyzed by GraphPad Prism 8.3 (GraphPad Software, San Diego, CA, 
USA), using Kruskal-Wallis test by ranks, followed by Dunn’s multiple comparisons test. Significant 
P-values were illustrated as * p < 0.05, ** p < 0.005, *** p < 0.0005 and **** p < 0.0001. 
3. Results 
3.1. OMVs are Suc es fully Isolated by Ultracentrifugation and SEC 
The OMVs were isolated from the myxobacterial cultures (Figure S1) and suc es ful y separated 
from fre  proteins remaining in the pel et by SEC (Figure S2), using our standardized protocol [3 ]. 
The Cbfe23     electron-dense, with a well delimited membrane, shown 
in the cryo-TEM micrographs (Figure 1). The ain fracti      150 n  in size 
(Figure S3). Cbfe23 OMVs had a zeta potential of −5.3 ± 0.7 mV while Cbv34 OMVs showed a zeta 
potential of −4.7 ± 0.6 mV, as recently reported by our group [3 ]. The liposomes used as a control for 
the uptake studies had a zeta potential of −24.5 ± 1.2 mV. 
 
Figure 1. Cryo-TEM micrographs of (a) Cbfe23 outer membrane vesicles (OMVs) and (b) Cbv34 
OMVs. Both OMVs are spherical and about 150 nm in size. Scale bars = 200 nm. 
3.2. Myxobacterial OMVs Neither Affect Viability of Mammalian Cells nor Induce Cytotoxicity 
The viability of alveolar epithelial cells A549, the macrophage cell line RAW 264.7 and 
differentiated THP-1 were investigated upon 24 h of incubation with different OMV concentrations 
(Figure 2). Cbv34 OMVs did not impact the viability of the cells at any concentration tested. The 
Cbfe23 OMVs were well tolerated until concentrations of 125,000 OMVs/cell. Very high amounts of 
OMVs (i.e., 125,000 OMVs/cell) decreased the macrophage cell line viability by 50% (Figure 2c,e), and 
by around 60% when incubated with A549 cells (Figure 2a). A comparable effect was observed for 
serial dilutions of cystobactamid, the natural compound previously identified in Cbv34 OMVs 
(Figure 2g) [33]. Cbv34 OMVs increased viability above 100% when incubated with dTHP-1 cells. We 
had previously observed this effect, which may be due to the nutrient bolus of lipids provided by 
high amounts of OMVs [33]. To further evaluate this effect, the cytotoxicity was assessed by LDH 
assay. As seen in Figure 2b,d,f, we did not detect any underlying cytotoxicity in all concentrations of 
OMVs tested and a similar result was obtained from different concentrations of cystobactamid 
(Figure 2h). 
3.3. Proinflammatory Cytokine Detection by Flow Cytometry 
Figure 1. r o- icrographs of (a) Cbfe23 outer me brane vesicles (OMVs) and (b) Cbv34 OMVs.
Both OMVs are spherical and bout 150 nm in size. Scale bars = 200 nm.
3.2. Myxobacterial OMVs Neither Affect Viability of Mammalian Cells nor Induce Cytotoxicity
The viability of alveolar epithelial cells A549, the macrophage cell line RAW 264.7 and differentiated
THP-1 were investigated upon 24 h of incubation with different OMV concentrations (Figure 2). Cbv34
OMVs did not impact the viability of the cells at any concentration tested. The Cbfe23 OMVs were
well tolerated until concentrations of 125,000 OMVs/cell. Very high amounts of OMVs (i.e., 125,000
OMVs/cell) decreased the macrophage cell line viability by 50% (Figure 2c,e), and by around 60%
when incubated with A549 cells (Figure 2a). A comparable effect was observed for serial dilutions of
cystobactamid, the natural co pound previously identified in Cbv34 OMVs (Figure 2g) [33]. Cbv34
OMVs increased viability above 100% when incubated with dTHP-1 cells. We had previously observed
this effect, which may be due to the nutrient bolus of lipids provided by high amounts of OMVs [33].
To further evaluate this effect, the cytotoxicity was assessed by LDH assay. As seen in Figure 2b,d,f, we
did not detect any underlying cytotoxicity in all concentrations of OMVs tested and a similar result
was obtained from different concentrations of cystobactamid (Figure 2h).
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3.3. Proinflammatory Cytokine Detection by Flow Cytometry
To better understand the effect that OMVs may have on primary immune cells, we isolated
peripheral blood mononuclear cells and incubated them with different concentrations of myxobacterial
OMVs. As seen in Figure 3, in comparison to the positive control lipopolysaccharide, we only observed
a tendency for the stimulation of release of TNF-alpha, IL-8, IL-6 and IL-1beta. Only at concentrations of
1 × 1013 particles/mL of Cbv34 OMVs, an increase in production of IL-1beta was found. The treatment
with high concentrations of OMVs (1 × 1013 particles/mL) seemed to affect the viability of PBMCs,
as seen by light microscopy (Figure S5).
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3.4. Myxobacterial OMVs Are Able to Kill Planktonic . s
OMVs had a killing effect at concentrations of approximately 1 × 1012 particles/mL. This correlates
to a ratio of 3 × 103 particles per CFU of S. aureus (Figure 4). We credit this effect to the cystobactamid
compounds found in the OMV pellets (Figure S6). We were further interested to see if the antibacterial
effect of myxobacterial OMVs is preserved during storage. For this, we tested whether Cbv34 OMVs are
active against E. coli DH5-alpha after storage at 4 ◦C for up to 28 days based on our recent protocol [33].
Under these conditions, the antimicrobial activity of the OMVs remained potent and dose-dependent
over time (Figure 5).
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Figure 4. Antibacterial activity of Cbfe23 and Cbv34 OMVs against S. aureus strain Newman after 4 h
of incubation at 37 ◦C. Mean ± SEM, n = 3. Significance was defined in comparison to the PBS control
(black column) as * p-value < 0.05, *** p < 0.0005, **** p-value < 0.0001 and ns = not significant.
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Figure 5. Antibacterial activity of Cbv34 OMVs against E. coli DH5-alpha right after isolation (fresh),
and upon storage at 4 ◦C for 7, 14, 21 and 28 days. The treatment was done for 18 h at 37 ◦C.
Mean ± SEM, n = 3.
3.5. OMVs Are Taken Up by Mammalian Cells
The interaction with and uptake of the OMVs in A549 epithelial cells and RAW 264.7 immune cells
were assessed by flow cytometry (Figures 6 and 7) and CLSM (Figure 8). In comparison to liposomes
prepared from bacterial phospholipids, we observed a significantly slower uptake of OMVs in A549
cells at 4 and 24 h of incubation (Figure 6a,d). The MFI of the liposomes was significantly higher when
compared to the OMVs at the 4 h time point with A549 cells (Figure 6b). The MFI difference remained
high between Cbv34 OMVs and liposomes at 24 h, but it was not significant when Cbfe23 OMVs
and liposomes were compared (Figure 6e). As for the uptake into RAW 264.7 cells, Cbfe23 OMVs
and bacterial liposomes did not show any significant difference in terms of percentage of positive
cells and MFI (Figure 7), both having a percentage of positive cells of nearly 90% at 4 h incubation
time (Figure 7a). However, Cbv34 OMVs had a significantly lower percentage of positive cells when
compared to the bacterial liposomes at 4 h (Figure 7a) and lower MFI at 24 h (Figure 7e). At the 24 h
time point, all particles led to 100% of fluorescent cells with RAW 264.7 cells (Figure 7d). MFI remained
comparable between all the samples at the 4 h time point (Figure 7b). The representative histograms of
the uptake of DiI-stained particles in A549 cells (Figure 6c,f) and RAW 264.7 cells (Figure 7c,f) show the
shift in the histograms of the samples compared to the untreated control (red).
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removal of OMVs by PBS washing during the staining process, which may indicate that they are 
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As for the localization of the particles it i t e cells, we observed little fluorescence signal
coming from the particles after 4 h of incubation with A549 (Figure S7), and a higher fluorescence
of Cbfe23 OMVs when incubated with RAW 264.7 cells for 4 h (Figure S8), when compared to the
Cbv34 OMVs. Even though we saw DiI-stained Cbv34 and Cbfe23 OMVs within the cells, we did
not observe colocalization with the cytoskeleton at any investigated time point (Figure 8). We noticed
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a removal of OMVs by PBS washing during the staining process, which may indicate that they are
mostly bound onto the cell surface. When the cells were washed once with PBS and fixed, we observed
a high number of fluorescent particles in A549 cells (Figures S9 and S10).Cells 2019, 8, x FOR PEER REVIEW 13 of 19 
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3.6. OMVs Are Able to Kill Intracellular Pathogens 
We investigated the ability of myxobacterial OMVs to treat intracellular infections caused by S. 
aureus in A549 cells. The most active concentrations were 108 OMVs/mL and 1011 OMVs/mL for 
Cbfe23 and Cbv34 OMVs, respectively (Figure 9). The highest concentrations of Cbfe23 OMVs were 
Figure 8. Uptake of fluorescent particles investigated by confocal laser scanning microscopy (CLSM)
after 24 h of incubation with (a) A549 and (b) RAW 264.7 cells. The cells nuclei are stained with DAPI
(blue), while the F-actin is labelled with Alexa Fluor 488 Phalloidin (green). OMVs and bacterial
liposomes are stained with DiI (red). Scale bar = 100 µm.
3.6. OMVs Are Able to Kill Intracellular Pathogens
We investigated the ability of myxobacterial OMVs to treat intracellular infections caused by
S. aureus in A549 cells. The most active concentrations were 108 OMVs/mL and 1011 OMVs/mL
Cells 2020, 9, 194 13 of 17
for Cbfe23 and Cbv34 OMVs, respectively (Figure 9). The highest concentrations of Cbfe23 OMVs
were not tested, because they negatively influenced the viability of the cells, as shown in Figure 2a.
Gentamicin is soluble in water, while cystobactamid is dissolved in DMSO (dimethyl sulfoxide), so we
included DMSO as a solvent control. The DMSO might contribute to the antibacterial effect of the free
cystobactamid, as we observed a tendency of lower CFU amounts in the DMSO sample alone. Both
free gentamicin and cystobactamid, together with the solvent control DMSO, were not significantly
different when compared among themselves. Our OMVs, which are in aqueous suspension, showed
a more pronounced reduction in bacterial growth compared to free antibiotics. By comparing this
with the number of bacteria present in the cells after 2 h of uptake (time zero), we see that the effect of
the OMVs against S. aureus is bacteriostatic. This effect was also confirmed by the statistical analysis,
which did not show a significant difference in bacterial growth between the most effective OMV
concentrations and the time zero control (blue dashed line in Figure 9).
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4. Discussion 
Cbv34 and Cbfe23 OMVs were successfully isolated by differential centrifugation and SEC, 
presenting a size of approximately 120–150 nm, which is an advantageous size for interaction with 
target cells and accumulation in inflamed infectious tissue [37]. The Cryo-TEM images showed 
spherical forms for Cbv34 OMVs, but for Cbfe23 OMVs, rod-shaped particles were also seen (Figure 
S4). We suspect that these particles might be fragments of outer membrane tubes (OMTs), which are 
known to be produced by some myxobacterial strains [38]. 
As for the viability and cytotoxicity, we showed low to absent toxicity for Cbv34 OMVs, as also 
reported in literature [33]. Cbfe23 OMVs, which were studied here for the first time, reduced the 

































































Figure 9. Antibacterial effect of OMVs against intracellular S. aureus after 24 h of treatment. Mean ± SEM,
n = 3–4 independent experiments. Significance was defined in relation to the PBS control as ns = not
significant, * p-value < 0.05, *** p-value < 0.0005 and **** p-value < 0.0001. Red dashed lines represent
the comparison between gentamicin 10 µg/mL, cystobactamid 10 µg/mL and the DMSO control = not
significant. Blue dotted lines represent the comparison between the time zero (2 h bacterial uptake),
Cbfe23 108 particles/mL and Cbv34 1011 particles/mL.
4. Discussion
Cbv34 and Cbfe23 OMVs were successfully isolated by differential centrifugation and SEC,
presenting a size of approximately 120–150 nm, which is an advantageous size for interaction with
target cells and accumulation in inflamed infectious tissue [37]. The Cryo-TEM images sho ed
spherical forms for Cbv34 OMVs, but for Cbfe23 OMVs, rod-shaped particles were also seen (Figure S4).
We suspect that these particles might be fragments of outer membrane tubes (OMTs), which are known
to be produced by some myxobacterial strains [38].
As for the viability and cytotoxicity, we showed low to absent toxicity for Cbv34 OMVs, as also
reported in literature [33]. Cbfe23 OMVs, which were studied here for the first time, reduced the
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viability of the cells only at a concentration of 125,000 OMVs/cell. This might be caused by a higher
load of antibiotic in comparison to Cbv34 OMVs, since we could see that a concentration of 10 µg/mL
cystobactamid also had a similar negative effect on cell viability. No dramatic cytotoxicity was detected
at any concentrations tested for either OMV. We have tested whether our OMVs induce the production
of proinflammatory cytokines to better understand the potential immunogenicity of our carriers. IL-6,
which is a multifunctional cytokine, and TNF, are released in response to inflammation and mediate
reactions to its effects, such as fever [39,40]. IL-8 and IL-1b induce chemotaxis and play a key role
in inflammation, recruiting neutrophils to the site of infection [41–43]. Our OMVs promoted a mild
release of proinflammatory cytokines compared to the LPS control. As an exception, the concentration
of 1013 Cbfe23 OMVs/mL stimulated a high production of IL-1beta, but possibly induced cell death, as
observed by light microscopy (Figure S5). IL-1beta is known to be negatively influenced in production
by the use of molecules that induce autophagy [44], which contributes to cell survival. This result might
also lead to a clue about the mechanisms of how Cbfe23 OMVs induce cell death at high concentrations.
Even though high concentrations of OMVs were needed to inhibit the growth of planktonic
bacteria, concentrations of 1012 OMVs/mL and higher did not seem to be required for an antibacterial
effect against intracellular pathogens. When intracellular CFUs were assessed to investigate the OMVs’
activity against S. aureus, a bacterial growth inhibition was identified, especially from Cbfe23 OMVs.
In literature, the Cbfe23 strain has not been reported to produce cystobactamids [45]. Here, we modified
the composition of the bacterial culture medium by using phytone as a carbon source, instead of the
previously reported skimmed milk and soy flour [45]. Due to this modification, we were able to identify
cystobactamids 919-1 and 920-1 [46–48] as the active compounds in the OMV extract (Figure S6).
For the potential application of OMVs as an antibacterial therapy in the clinic, their formulations must
be stable for a certain period, preferably without any special storage conditions, such as deep freezing
at −80 ◦C and the use of cryoprotectants. Since we have already showed an antibacterial effect of
Cbv34 OMVs against E. coli [26] and the easy handling of this bacterium, we investigated OMV storage
stability at 4 ◦C with this model pathogen. We found that the dose-dependent antibacterial activity of
Cbv34 OMVs was conserved during 28 days of storage. This result matches recent findings that show
extracellular vesicles’ inherent stability under different storage conditions [49,50].
Compared to bacteriomimetic liposomes, OMVs showed different uptake kinetics with immune
and epithelial cells. While liposomes are rapidly taken up in all cell types at high amounts, OMVs
seemed to have a preferentially better uptake in immune cells than in epithelial cells. Surface charge
may play a role in this mechanism, but surface proteins of OMVs are also important for this effect,
as was shown for mammalian vesicles [51]. As we show, OMVs have an antibacterial effect against
internalized S. aureus in A549 cells. Both Cbfe23 and Cbv34 OMVs showed a higher antibacterial effect,
when compared to the untreated control, than the free gentamicin and cystobactamid. Free antibiotics
generally have a low permeation through mammalian cell membranes and thus favor intracellular
infections, which may become persistent and difficult to treat. The use of myxobacterial OMVs as
nanocarriers could possibly overcome the cellular barrier and successfully deliver the antibacterial
compound to the lungs, potentially being administered locally as an aerosol.
The next steps to further evaluate myxobacterial OMVs as drug carriers are to rule out their
immunogenicity in complex in vitro models of inflammation [52], and the evaluation of their
antibacterial activity in an infected animal model.
5. Conclusions
OMVs from Cbv34 and Cbfe23 are not only low in toxicity in different cell lines, but also in
primary immune cells. They are able to mediate killing of one of the most important Gram-positive
problem pathogens, S. aureus. These OMVs are able to be taken up into infected cells and showed
efficient bacteriostatic effect against intracellular S. aureus infections.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/1/194/s1,
Figure S1: Morphology of Cbfe23 (passage 3, 5 days in culture) and Cbv34 (passage 9, 7 days in culture),
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Figure S2: Particle size measured by dynamic light scattering and protein concentration of Cbfe23 size exclusion
chromatography fractions (1 mL each) were measured by BCA (bicinchoninic acid) assay (Sigma-Aldrich Co., St.
Louis, MO, USA), Figure S3: Representative graphs of size distributions measured by nanoparticle tracking analysis
of a) Cbv34 and b) Cbfe23 OMVs, Figure S4: Cryo-TEM micrographs of Cbfe23 pellets after ultracentrifugation,
Figure S5: Light microscopy images showing the morphology of peripheral blood mononuclear cells (PBMCs) after
4 h treatment with OMVs and controls, Figure S6: a) LC-MS Base peak chromatogram of the OMV extract (black)
highlighting the two major cystobactamids: cystobactamid 919-1 (A, red, m/z 920.31 ± 0.05 Da) and cystobactamid
920-1 (B, blue, m/z 921.30 ± 0.05 Da) as extracted ion chromatograms, Figure S7: Uptake/interaction of OMVs
and liposomes with A549 cells after 4 h incubation measured by confocal laser scanning microscopy, Figure S8:
Uptake/interaction of OMVs and liposomes with RAW 264.7 cells after 4 h of incubation measured by confocal
laser scanning microscopy, Figure S9: Uptake/interaction imaging of OMVs and liposomes after 4 h incubation
with A549, following one single wash with PBS and fixation by confocal laser scanning microscopy, Figure S10:
Uptake/interaction imaging of OMVs and liposomes after 24 h incubation with A549, following one single wash
with PBS and fixation by confocal laser scanning microscopy.
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